High Sensitivity TSO500 Detection of Somatic Variants in Matched FFPE and Plasma: Implications for Liquid Biopsy Biomarker Evaluations

Online (EST)


11:0am - 12:0pm and Discovery Life Sciences present an upcoming webinar with speaker, Dr. Shawn Levy. Discovery Life Sciences has developed a new research solution that leverages Illumina’s TruSight Oncology 500 (TSO00) Solid Tumor (FFPE) and cfDNA technology to identify germline and somatic variants from both DNA and RNA. Attendees of this webinar will learn how to use Discovery’s unique services to advance their biomarker programs. Register now to join the event and learn more about this new technology.

Click Here for More Information

Contact: Jessie McConville
Contact Email: